// AST – IMS - [DMinute_ROS]

Bokf Maintains Stake in Arista Networks (ANET); Baillie Gifford & Company Raised Vertex Pharmaceuticals (VRTX) Position by $3.13 Million as Share Price Declined

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo

Baillie Gifford & Company increased its stake in Vertex Pharmaceuticals (VRTX) by 2.82% based on its latest 2018Q3 regulatory filing with the SEC. Baillie Gifford & Company bought 16,288 shares as the company’s stock declined 3.07% with the market. The institutional investor held 594,727 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $114.63 million, up from 578,439 at the end of the previous reported quarter. Baillie Gifford & Company who had been investing in Vertex Pharmaceuticals for a number of months, seems to be bullish on the $47.30B market cap company. The stock decreased 1.64% or $3.09 during the last trading session, reaching $185.07. About 895,214 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 25.22% since January 14, 2018 and is uptrending. It has outperformed by 25.22% the S&P500. Some Historical VRTX News: 27/04/2018 – Top 3 today — #1 Vertex’s rapid-fire PhIII program hits a roadblock at the FDA. Will regulators force rival Galapagos to slow down too? $VRTX $GLPG; 26/04/2018 – VERTEX PHARMACEUTICALS INC – COMPANY REITERATES FULL-YEAR 2018 TOTAL CF PRODUCT REVENUE GUIDANCE OF $2.65 BLN TO $2.80 BLN; 09/03/2018 – L3 management meets with bidders for Vertex divest; 06/04/2018 – STAT Plus: New York panel to review Vertex pricing in first test of new law; 26/04/2018 – Vertex’s latest cystic fibrosis drug reports strong sales in first quarter since approval; 20/03/2018 – STAT Plus: Vertex battles with the U.K. over the price of its cystic fibrosis drug; 30/05/2018 – S&PGR Rates Vertex Aerospace Services ‘B’, Pos Outlook; 31/05/2018 – Plu s- UPDATED: FDA slaps a clinical hold on sickle cell IND filed for a new gene therapy from Vertex and CRISPR Therapeutics $VRTX $CRSP; 29/05/2018 – Opiant Pharmaceuticals to Participate in The American Society of Clinical Psychopharmacology 2018 Annual Meeting; 14/05/2018 – Fundlogic Adds Wells Fargo, Exits Cigna, Cuts Vertex: 13F

Bokf increased its stake in Arista Networks Inc (ANET) by 6.87% based on its latest 2018Q3 regulatory filing with the SEC. Bokf bought 3,179 shares as the company’s stock declined 14.59% with the market. The institutional investor held 49,469 shares of the technology company at the end of 2018Q3, valued at $13.15 million, up from 46,290 at the end of the previous reported quarter. Bokf who had been investing in Arista Networks Inc for a number of months, seems to be bullish on the $16.39 billion market cap company. The stock decreased 0.36% or $0.8 during the last trading session, reaching $217.3. About 161,064 shares traded. Arista Networks, Inc. (NYSE:ANET) has risen 4.51% since January 14, 2018 and is uptrending. It has outperformed by 4.51% the S&P500. Some Historical ANET News: 03/05/2018 – Arista Networks 1Q Net $144.5M; 28/03/2018 – ARISTA: ITC ALJ SUPPORTS SUSPENSION OF REMEDIES ON CISCO PATENT; 09/04/2018 – Gold Resource Corporation Extends Arista Vein System High-Grade With Intercepts Including 2 Meters of 6.68 g/t Gold and 864 g/t; 16/05/2018 – Arista Networks Presenting at Bank of America Conference Jun 5; 13/04/2018 – Microsoft represented 16 percent of Arista’s revenue in 2017; 03/05/2018 – Arista Networks 1Q Rev $472.5M; 08/05/2018 – Tech Today: Arista Storms Cisco’s Turf, Impinj Soars, Snap’s New Blood — Barron’s Blog; 19/03/2018 Tech Today: Bad Facebook, Oracle On Tap, Buying II-VI, Selling Arista — Barron’s Blog; 13/04/2018 – Tech Today: Arista Cut, Defending Facebook, Amazon’s Postal Math — Barron’s Blog; 07/05/2018 – Arista Introduces Cognitive Cloud Networking for the Campus

Among 31 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 5 Hold. Therefore 84% are positive. Vertex Pharmaceuticals had 115 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by BMO Capital Markets on Friday, October 20. As per Tuesday, March 13, the company rating was maintained by Cowen & Co. As per Tuesday, December 18, the company rating was maintained by Guggenheim. The rating was upgraded by Oppenheimer on Thursday, February 1 to “Buy”. The rating was maintained by Maxim Group with “Buy” on Wednesday, January 31. The stock has “Buy” rating by Jefferies on Wednesday, October 5. As per Tuesday, March 8, the company rating was maintained by Leerink Swann. Jefferies initiated it with “Hold” rating and $130 target in Wednesday, September 9 report. As per Wednesday, January 31, the company rating was maintained by Jefferies. BMO Capital Markets maintained the stock with “Buy” rating in Monday, September 25 report.

Investors sentiment decreased to 1.06 in 2018 Q3. Its down 0.24, from 1.3 in 2018Q2. It dropped, as 42 investors sold VRTX shares while 192 reduced holdings. 73 funds opened positions while 176 raised stakes. 231.66 million shares or 2.06% less from 236.55 million shares in 2018Q2 were reported. Mufg Americas Corp owns 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 70 shares. Proshare Lc stated it has 0.32% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Cannell Peter B And has invested 0.01% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Washington Trust Financial Bank reported 100 shares. Arrow Financial owns 330 shares. Bowen Hanes And has 165,000 shares. Element Cap Mgmt Lc reported 1,674 shares stake. First Long Island Lc accumulated 1,230 shares. Whittier Trust Co Of Nevada stated it has 285 shares or 0% of all its holdings. Intact Invest Mgmt Inc accumulated 1,190 shares. Kelly Lawrence W & Assoc Ca invested 0.36% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Gateway Invest Advisers Lc accumulated 132,114 shares. Northcoast Asset Mngmt Ltd Liability Com invested 0.04% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Mackenzie Fincl reported 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Schroder Investment Mngmt Gp holds 0.01% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 33,635 shares.

Baillie Gifford & Company, which manages about $92.61B US Long portfolio, decreased its stake in Dexcom Inc (NASDAQ:DXCM) by 103,870 shares to 5.09M shares, valued at $728.67M in 2018Q3, according to the filing. It also reduced its holding in Bluebird Bio Inc (NASDAQ:BLUE) by 199,871 shares in the quarter, leaving it with 4.64 million shares, and cut its stake in American Express (NYSE:AXP).

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Fool.com which released: “Forget CRISPR Therapeutics: Vertex Pharmaceuticals Incorporated Is a Better Biotech Stock – Motley Fool” on September 05, 2018, also Streetinsider.com with their article: “Vertex Pharma (VRTX) will Submit ORKAMBI as well as SYMKEVI to be Used in Combination with ivacaftor to Scottish Medicines Consortium for Appraisal – StreetInsider.com” published on December 19, 2018, Streetinsider.com published: “Vertex Pharma (VRTX) Expands Current Partnership with X-Chem Inc. – StreetInsider.com” on January 04, 2019. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Nasdaq.com and their article: “VRTX March 1st Options Begin Trading – Nasdaq” published on January 10, 2019 as well as Nasdaq.com‘s news article titled: “July 6th Options Now Available For Vertex Pharmaceuticals (VRTX) – Nasdaq” with publication date: May 24, 2018.

Since July 16, 2018, it had 0 insider buys, and 20 sales for $8.50 million activity. 1,076 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $207,926 were sold by Graney Thomas. $430,920 worth of stock was sold by Kewalramani Reshma on Monday, October 8. Parini Michael had sold 4,250 shares worth $814,215. Another trade for 61 shares valued at $9,989 was made by Sachdev Amit on Thursday, November 15. The insider Silva Paul M sold 809 shares worth $150,895. Another trade for 5,803 shares valued at $998,580 was made by Arbuckle Stuart A on Monday, November 5.

More notable recent Arista Networks, Inc. (NYSE:ANET) news were published by: Seekingalpha.com which released: “Arista Q3 Earnings: The Price Of Excellence – Seeking Alpha” on November 04, 2018, also Seekingalpha.com with their article: “Arista Networks: Ignore The Noise – Seeking Alpha” published on May 07, 2018, Seekingalpha.com published: “Arista Enters Into The WiFi Business – Seeking Alpha” on August 03, 2018. More interesting news about Arista Networks, Inc. (NYSE:ANET) were released by: Seekingalpha.com and their article: “Arista: A Recovery Is In Sight – Seeking Alpha” published on November 04, 2018 as well as Seekingalpha.com‘s news article titled: “SBUX, SLS, EXEL among premarket’s big gainers – Seeking Alpha” with publication date: November 02, 2018.

Bokf, which manages about $3.98B US Long portfolio, decreased its stake in Amgen Inc (NASDAQ:AMGN) by 4,915 shares to 71,646 shares, valued at $14.85 million in 2018Q3, according to the filing. It also reduced its holding in Ishares Tr (AGG) by 8,677 shares in the quarter, leaving it with 227,331 shares, and cut its stake in Nuveen Amt Free Mun Cr Inc F (NVG).

Among 36 analysts covering Arista Networks (NYSE:ANET), 21 have Buy rating, 1 Sell and 14 Hold. Therefore 58% are positive. Arista Networks had 152 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Monday, August 7 by Instinet. UBS maintained it with “Neutral” rating and $200 target in Friday, November 3 report. The company was maintained on Friday, May 4 by KeyBanc Capital Markets. Stifel Nicolaus maintained the shares of ANET in report on Wednesday, March 8 with “Buy” rating. The stock of Arista Networks, Inc. (NYSE:ANET) has “Equal-Weight” rating given on Tuesday, September 4 by Morgan Stanley. As per Wednesday, October 14, the company rating was initiated by Barclays Capital. The company was maintained on Monday, September 18 by KeyBanc Capital Markets. Barclays Capital maintained the shares of ANET in report on Friday, August 4 with “Overweight” rating. On Friday, November 3 the stock rating was maintained by Cowen & Co with “Buy”. The rating was maintained by Credit Suisse on Thursday, May 31 with “Buy”.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.